Faculty of Dentistry, Department of Oral Medicine and Periodontology, Cairo University, Cairo, Egypt.
Clinic for Conservative Dentistry and Periodontology, Christian Albrechts-Universität zu, Kiel, Germany.
Clin Implant Dent Relat Res. 2021 Aug;23(4):520-529. doi: 10.1111/cid.12995. Epub 2021 Jun 8.
The ability to restore missing teeth with dental implants is dictated by the available bone and by the presence of anatomical structures. The potential to insert ultrashort implants avoids additional surgical procedures and its inherent complications. The last European Association of Dental Implantologists consensus in 2016 defined ultrashort implants and standard-length dental implants as <6 and >8 mm, respectively.
The present study aimed to investigate whether single standing ultrashort dental implants (US) could provide a viable therapeutic alternative to osteotome mediated sinus floor elevation in combination with standard-length dental implants (SL) 10 mm in posterior maxillary rehabilitation with reduced bone height.
The study was conducted as a prospective parallel group controlled clinical trial with a 12 month follow-up, where 48 implants were randomized into two groups; US-group (5.5 mm) and SL-group (10 mm) implants placed with osteotome-mediated sinus floor elevation. Crestal bone loss (CBL) was defined as the study's primary outcome, while implant survival, buccal bone thickness, implant stability, probing depth, gingival recession, and adverse effects were assessed as secondary outcomes.
Mesial CBL was 1.13 ± 0.52 mm in SL- and 0.72 ± 0.52 mm in US-group (P = .021), while distal CBL was 1.44 ± 0.72 mm in SL- and 0.91 ± 0.69 mm in US-group at 12 months (P = .0179). Regarding implant stability, probing depth, and gingival recession there was no statistically significant difference between the two groups. Regarding implants' survival, three implants were lost in the US-while only one implant was lost in the SL-group (P = .6085; Fisher's exact test). Nevertheless, the ultrashort implants were associated with a tripling of the failure rate and uncertainty where the true failure rate is uncertain (relative risk 3.0; confidence interval 0.3-26.8).
Within the current trial's limitations, US-appear appear promising as they are associated less postoperative discomfort, minimal invasiveness and less CBL. However, larger sample size is required to determine whether the ultrashort have an acceptable survival rate.
种植牙恢复缺失牙齿的能力取决于可用的骨量和解剖结构的存在。植入超短种植体的潜力避免了额外的手术和其固有的并发症。2016 年最后一次欧洲牙科种植学会共识将超短种植体和标准长度种植体定义为分别<6 和 >8mm。
本研究旨在探讨在骨量减少的后上颌骨修复中,与标准长度种植体(10mm)结合使用骨凿介导的窦底提升相比,单颗直立超短牙科种植体(US)是否可为牙槽骨高度降低的患者提供一种可行的治疗替代方案。
该研究为前瞻性平行组对照临床试验,随访 12 个月,48 个种植体随机分为两组;US 组(5.5mm)和 SL 组(10mm)种植体,采用骨凿介导的窦底提升。颊侧骨厚度、种植体稳定性、探诊深度、牙龈退缩和不良反应。
SL 组近中颊侧骨吸收量为 1.13±0.52mm,US 组为 0.72±0.52mm(P=0.021),SL 组远中颊侧骨吸收量为 1.44±0.72mm,US 组为 0.91±0.69mm(P=0.0179)。在种植体稳定性、探诊深度和牙龈退缩方面,两组间无统计学差异。关于种植体的存活率,US 组有 3 个种植体失败,而 SL 组只有 1 个种植体失败(P=0.6085;Fisher 确切检验)。然而,超短种植体的失败率增加了三倍,而且真实的失败率是不确定的(相对风险 3.0;置信区间 0.3-26.8)。
在本试验的局限性内,超短种植体具有较好的应用前景,因为它们术后不适较轻、创伤较小、颊侧骨吸收较少。然而,需要更大的样本量来确定超短种植体是否具有可接受的存活率。